Aberdeen Group plc Raises Stock Holdings in Ultragenyx Pharmaceutical Inc. $RARE

Aberdeen Group plc increased its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 4.6% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 501,056 shares of the biopharmaceutical company’s stock after acquiring an additional 22,152 shares during the period. Aberdeen Group plc owned approximately 0.53% of Ultragenyx Pharmaceutical worth $18,218,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in RARE. GAMMA Investing LLC raised its stake in Ultragenyx Pharmaceutical by 76.2% in the 1st quarter. GAMMA Investing LLC now owns 747 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 323 shares during the last quarter. Parallel Advisors LLC raised its stake in Ultragenyx Pharmaceutical by 1,061.9% in the 2nd quarter. Parallel Advisors LLC now owns 732 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 669 shares during the last quarter. ANTIPODES PARTNERS Ltd purchased a new position in Ultragenyx Pharmaceutical in the 1st quarter worth $57,000. Headlands Technologies LLC purchased a new position in Ultragenyx Pharmaceutical in the 1st quarter worth $59,000. Finally, Covestor Ltd raised its stake in Ultragenyx Pharmaceutical by 86.8% in the 1st quarter. Covestor Ltd now owns 1,711 shares of the biopharmaceutical company’s stock worth $62,000 after acquiring an additional 795 shares during the last quarter. Hedge funds and other institutional investors own 97.67% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently issued reports on RARE. Wells Fargo & Company reduced their target price on Ultragenyx Pharmaceutical from $88.00 to $65.00 and set an “overweight” rating for the company in a research note on Thursday, July 10th. Canaccord Genuity Group cut their price target on Ultragenyx Pharmaceutical from $136.00 to $128.00 and set a “buy” rating on the stock in a research report on Friday, August 8th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $105.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Friday, September 5th. HC Wainwright reaffirmed a “buy” rating and set a $80.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, September 9th. Finally, Morgan Stanley cut their price target on Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an “overweight” rating on the stock in a research report on Monday, July 14th. Eleven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $81.50.

Insider Transactions at Ultragenyx Pharmaceutical

In related news, CFO Howard Horn sold 7,942 shares of the firm’s stock in a transaction dated Monday, October 13th. The shares were sold at an average price of $31.51, for a total value of $250,252.42. Following the transaction, the chief financial officer directly owned 98,227 shares of the company’s stock, valued at approximately $3,095,132.77. This trade represents a 7.48% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Karah Herdman Parschauer sold 2,450 shares of the firm’s stock in a transaction dated Friday, September 12th. The shares were sold at an average price of $31.17, for a total transaction of $76,366.50. Following the completion of the transaction, the executive vice president directly owned 73,271 shares in the company, valued at $2,283,857.07. This represents a 3.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 10,456 shares of company stock worth $328,486 over the last 90 days. Insiders own 5.50% of the company’s stock.

Ultragenyx Pharmaceutical Stock Down 1.0%

NASDAQ:RARE opened at $31.69 on Wednesday. Ultragenyx Pharmaceutical Inc. has a 52 week low of $25.81 and a 52 week high of $57.99. The stock has a market capitalization of $3.05 billion, a PE ratio of -5.73 and a beta of 0.21. The stock’s 50-day moving average price is $29.88 and its 200-day moving average price is $32.93.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) EPS for the quarter, beating analysts’ consensus estimates of ($1.27) by $0.10. Ultragenyx Pharmaceutical had a negative return on equity of 237.48% and a negative net margin of 87.34%.The firm had revenue of $166.50 million for the quarter, compared to analysts’ expectations of $161.37 million. During the same period last year, the firm earned ($1.52) EPS. The company’s quarterly revenue was up 13.2% on a year-over-year basis. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS. Sell-side analysts expect that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current fiscal year.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.